Clinical Trials for Cervical Cancer

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced solid tumors or lymphoma and no remaining standard or curative treatment option receive oral VMD-928 monotherapy. Patients generally require TrkA overexpression or an NTRK1 fusion; VMD-928 is an investigational allosteric TrkA/NTRK1 inhibitor.

ClinicalTrials.gov ID: NCT03556228

A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, unresectable advanced or metastatic cancers harboring eligible KRAS non-G12C, BRAF, CRAF, or NRAS alterations receive oral BDTX-4933, an investigational RAF inhibitor designed to block signaling through active RAF dimers. Dose expansion is limited to patients with radiographically progressing KRAS non-G12C–mutant NSCLC.

ClinicalTrials.gov ID: NCT05786924

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung, and Other KK-LC-1 Positive Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable metastatic solid tumors expressing KK-LC-1 in ≥10% of tumor cells and carrying HLA-A*01:01, particularly those with gastric, non–small cell lung, triple-negative breast, or cervical cancer, may enroll after receiving or declining standard systemic therapy. Treatment consists of cyclophosphamide/fludarabine conditioning, a single infusion of autologous TCR-engineered T cells targeting an HLA-A*01:01–presented KK-LC-1 peptide, and aldesleukin.

ClinicalTrials.gov ID: NCT05483491

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent or metastatic GRPR-expressing mCRPC, HR-positive/HER2-negative breast cancer, colorectal cancer, cervical cancer, cutaneous melanoma, or NSCLC are eligible if they have a lesion with uptake greater than liver on GRPR imaging; recurrent disease must have progressed after at least two systemic therapies. Participants receive up to four cycles of investigational ²¹²Pb-DOTAM-GRPR1, a GRPR-targeted radiopharmaceutical that delivers DNA-damaging alpha radiation.

ClinicalTrials.gov ID: NCT05283330

A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with incurable locally advanced, recurrent, or metastatic solid tumors and ECOG performance status 0–1 receive IV RO7502175 (enzelkitug) alone or with atezolizumab or pembrolizumab. RO7502175 is an investigational afucosylated anti-CCR8 antibody designed to deplete tumor-associated regulatory T cells.

ClinicalTrials.gov ID: NCT05581004

A Phase 1 Open-Label, Dose-Escalation and Dose-Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-Tumor Activity of IACS-6274 as Monotherapy and in Combination in Patients With Advanced Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated advanced solid tumors and ECOG performance status 0–1 receive IACS-6274, an investigational glutaminase-1 inhibitor, alone or with bevacizumab plus weekly paclitaxel or with the AKT inhibitor capivasertib. Combination cohorts focus on platinum-resistant ovarian cancer, KEAP1/NFE2L2-mutant non-small cell lung cancer, or low-ASNS high-grade serous ovarian cancer.

ClinicalTrials.gov ID: NCT05039801

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic solid tumors after standard treatment, or with no suitable standard option, receive intratumoral MQ710 alone or with pembrolizumab; combination cohorts focus on cutaneous squamous cell carcinoma, Merkel cell carcinoma, melanoma, and head and neck squamous cell carcinoma, generally after anti–PD-1 therapy. MQ710 is an engineered vaccinia-based virotherapy designed to enhance cGAS–STING signaling and antitumor T-cell activity; pembrolizumab blocks PD-1.

ClinicalTrials.gov ID: NCT05859074